3.18%XLF 16.61 6.69%QQQQ 33.28 4.53%
The Global Business News Leader | Tuesday, 7 Oct 2008
- EQUITY MARKETS
- BONDS AND RATES
- FOREX
- COMMODITIES
- LANGUAGES
- FUNDS
- RETIREMENT
- TAXES
- INSURANCE
- LANGUAGES
- MOVIE
- MUSIC
- TV
- CELEBRITIES
- LANGUAGES
MYLAN INC
MYL (NYSE)
$ 8.65 
Change: -0.35 -4.05% | Volume: 12,180,644
Change: -0.35 -4.05% | Volume: 12,180,644
MYLAN INC - Fundamental Profile
Company Information
| Ticker Symbol: | MYL |
|---|---|
| Exchange: | NYSE |
| Contact Info: | 1500 Corporate Drive Canonsburg PA 15317 724 514-1800 |
| CEO/President: | Robert J. Coury |
| Industry: | Medical - Generic Drugs / Standard Industry Code: 2834 |
| Description: | Mylan Inc. is one of the world\'s leading quality generic and specialty pharmaceutical companies. The Company offers one of the industry\'s broadest and highest quality product portfolios, a robust product pipeline and a global commercial footprint through operations in more than 90 countries. Through its controlling interest in Matrix Laboratories Limited, Mylan has direct access to one of the largest active pharmaceutical ingredient manufacturers in the world. Dey L.P., Mylan\'s fully integrated specialty business, provides the Company with innovative and diversified opportunities in the respiratory and allergy therapeutic areas. |
Share Information
| Shares Outstanding: | 304,450 (000) | Market Value: | 3,127,100 ($000) |
|---|---|---|---|
| Percentage of Inst.Shareholders: | 96.10% | Number of Inst.Shareholders: | 6.00% |
| Last Quarter Sales: | 1203.12 ($Mil.) | Last Quarter Net Income: | 26.39 ($Mil.) |
| Last Quarter EPS: | 0.16 | P/E Ratio: | 15 |
| Most Recent Earnings: | 0.16 on 08/06/08 | Earnings Per Share: | -5.93 |
| Most Recent Split: | 3-2 on 10/09/03 | Annual Dividend Rate: | 0 |
| Most Recent Dividend: | 0.060 on 06/27/07 | Annual Dividend Yield: | 0% |
Data Provided By Barchart.com
CoreData does not represent, warrant, or guarantee completeness, accuracy or timeliness of its data, and shall have no liability of any kind whatsoever to any party on account of any incompleteness of, inaccuracies in or untimeliness of the CoreData content provided hereunder, or for any delay in reporting such data. CoreData expressly disclaims all warranties of fitness of the CoreData content or computations and analyses thereof for a particular purpose or use.
Most Popular 
MYL
Companies
IBT
- Teva says it has lost exclusivity on Risperdal
- Ahead of the Bell: Generic drug makers
- AIG, Circuit City, Morgan Stanley among big movers
- Obama, McCain advisers agree...on generic drugs
- More consolidation seen in generic drug industry
- Mylan says FDA approves its generic Risperdal
- Mylan shares rise as rival Ranbaxy gets FDA ban
- Bio Box: Neel Kashkari
- US financial bailout: It is rocket science
- Wachovia, Citigroup, Wells agree to standstill
- Moody's may downgrade Lilly after ImClone buyout
- Oil prices fall as financial turmoil goes global
- Allianz investing $2.5B in Hartford Financial
- Dutch insurer Aegon's shares hit hardest in rout
- Obama Ad Questions McCains Judgment, Values in Keating 5 Ethics Scandal
- VIDEO: Will Smith Beams with Pride over Tyler Perrys Studio
- Obamas New Ad Attacks McCain with Keating 5 Ethics Scandal
- Sarah Palin Takes Tina Feys Jokes Lightly
- Tyler Perry Becomes First African-American Major Film Studio Owner
- Fundamental analysis for precious metals gold - 10/7/2008
- Fundamental analysis for precious metals silver - 10/7/2008
Top Competitors
| MYLAN INC |  |
-38.80 | 10.27 |
| TEVA PHARM INDS |  |
+4.70 | 46.08 |
| BARR PHARMA INC | |
+1.80 | 64.10 |
| ALPHARMA INC | |
+42.30 | 34.86 |
| WATSON PHARMACE | |
-12.10 | 27.54 |
Partners  
|
© 2008 The Ibtimes Company. All Rights Reserved. Terms of service | Privacy Policy | Advertising | About Us | Contact Us | Archives